跳至主要内容
临床试验/NCT06994767
NCT06994767已完成不适用

Speech-derived Digital Biomarkers for Assessing Mild Cognitive Impairment and Alzheimer's Disease Diagnosis Accuracy

Hackensack Meridian Health1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2025年5月19日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
150
试验地点
1
主要终点
The primary objective of the study is to assess the sensitivity biomarkers in patients with MCI and AD diagnosis

研究概览

简要总结

The goal is to assess the accuracy of an application that analyzes voice characteristics to diagnose patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD). The main question is whether the application's diagnosis is the same as the clinician's for MCI and AD patients.

详细描述

The study aims to assess the sensitivity and specificity of an application that uses vocal biomarkers to diagnose patients with mild cognitive impairment (MCI) and Alzheimer's disease. The application will use clinically validated survey instruments and voice recordings to determine the disease status of patients with MCI and Alzheimer's disease. The diagnosis developed by the application is the primary outcome variable. To determine the sensitivity and specificity, the application diagnosis will be compared against the physician's clinical diagnosis.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Males and females between the ages of 50 and above
  • •Willing and capable of participating in all aspects of the study
  • •Willing and capable of giving informed consent
  • •Diagnosis of MCI or Alzheimer's by the physician
  • •For the control group: Without diagnosis of MCI or Alzheimer's or other types of dementia
  • •Subjects are free of any medical condition(s) that, according to

排除标准

  • •, might audibly affect voice characteristics
  • •Subject must be able to speak and read with fluency in the English language.
  • •Exclusion Criteria:
  • •All participants below 50 years
  • •Failure to provide informed consent
  • •Individuals with the following medical conditions will be excluded:
  • •i) Parkinson's disease ii) Huntington's disease iii) Cancer and active cancer treatments
  • •Persons with speech characteristics (heavy accents, slurring, stuttering, etc.) that would interfere with voice recording or voice analysis

研究组 & 干预措施

Healthy Volunteers

Active Comparator

Patients without a diagnosis of MCI or Alzheimer's, or other types of dementia

干预措施: The Canary Application (Other)

Mild Cognitive Impairment (MCI)

Experimental

Patients with a mild congitive impairment

干预措施: The Canary Application (Other)

Alzheimer's Disease

Experimental

Patients with an Alzheimer's Disease diagnosis

干预措施: The Canary Application (Other)

结局指标

主要结局

The primary objective of the study is to assess the sensitivity biomarkers in patients with MCI and AD diagnosis

时间窗: Upon enrollment

The CANARY application will use clinically validated survey instruments and voice recordings to analyze the data and determine the patient's MCI/ Alzheimer's disease diagnosis. The diagnosis developed by the application is the primary outcome variable. To determine the sensitivity, the application diagnosis will be compared against the clinical diagnosis of the physician.

The primary objective of the study is to assess the specificity of vocal biomarkers in patients with MCI and AD diagnosis

时间窗: Upon enrollment

The CANARY application will use clinically validated survey instruments and voice recordings to analyze the data and determine the patient's MCI/ Alzheimer's disease diagnosis. The diagnosis developed by the application is the primary outcome variable. To determine the specificity, the application diagnosis will be compared against the clinical diagnosis of the physician.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验